GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (NAS:LNTH) » Definitions » Inventory-to-Revenue

LNTH (Lantheus Holdings) Inventory-to-Revenue : 0.18 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Lantheus Holdings's Average Total Inventories for the quarter that ended in Dec. 2024 was $69 Mil. Lantheus Holdings's Revenue for the three months ended in Dec. 2024 was $391 Mil. Lantheus Holdings's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.18.

Lantheus Holdings's Inventory-to-Revenue for the quarter that ended in Dec. 2024 declined from Sep. 2024 (0.19) to Sep. 2024 (0.18)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Lantheus Holdings's Days Inventory for the three months ended in Dec. 2024 was 44.44.

Inventory Turnover measures how fast the company turns over its inventory within a year. Lantheus Holdings's Inventory Turnover for the quarter that ended in Dec. 2024 was 2.05.


Lantheus Holdings Inventory-to-Revenue Historical Data

The historical data trend for Lantheus Holdings's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Inventory-to-Revenue Chart

Lantheus Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.08 0.04 0.04 0.04

Lantheus Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.18 0.18 0.19 0.18

Competitive Comparison of Lantheus Holdings's Inventory-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantheus Holdings's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's Inventory-to-Revenue falls into.


;
;

Lantheus Holdings Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lantheus Holdings's Inventory-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Inventory-to-Revenue (A: Dec. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2023 ) + Total Inventories (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )
=( (64.029 + 68.025) / 2 ) / 1533.91
=66.027 / 1533.91
=0.04

Lantheus Holdings's Inventory-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue (Q: Dec. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Sep. 2024 ) + Total Inventories (Q: Dec. 2024 )) / count ) / Revenue (Q: Dec. 2024 )
=( (70.835 + 68.025) / 2 ) / 391.11
=69.43 / 391.11
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lantheus Holdings  (NAS:LNTH) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Lantheus Holdings's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2024 )/Cost of Goods Sold (Q: Dec. 2024 )*Days in Period
=69.43/142.565*365 / 4
=44.44

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Lantheus Holdings's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2024 ) / Average Total Inventories (Q: Dec. 2024 )
=142.565 / 69.43
=2.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lantheus Holdings Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantheus Holdings Business Description

Traded in Other Exchanges
Address
201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Executives
Marshall Robert J. Jr. officer: CFO and Treasurer C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Mary Anne Heino director, officer: CEO and President C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Paul Blanchfield officer: Chief Commercial Officer C/O LANTHEUS HOLDINGS, INC., 331, NORTH BILLERICA MA 01862
James H Thrall director 343 COMMERCIAL STREET #314, BOSTON MA 02109
Daniel Niedzwiecki officer: See Remarks C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Andrea Sabens officer: Chief Accounting Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Gary J Pruden director ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Heinz Christoph Maeusli director SCHUETZENWEG 3, ENGELBURG V8 9032
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sam R Leno director C/O BOSTON SCIENTIFIC CORPORATION, ONE BOSTON SCIENTIFIC PLACE, NATICK MA 01760
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Etienne Montagut officer: See Remarks C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Brian A Markison director 501 FIFTH STREET, BRISTOL TN 37620
Jean-claude Provost officer: Chief Medical Officer C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON RD, SOUTH BUILDING, BEDFORD MA 01730